The BTC transfers landed just before the Fed’s rate cut, adding tension to a market already shaken by volatility and macro uncertainty.The BTC transfers landed just before the Fed’s rate cut, adding tension to a market already shaken by volatility and macro uncertainty.

SpaceX, BlackRock Shift $296M in Bitcoin: Sell-Off Signal Ahead?

2025/12/12 04:45
3 min read

SpaceX and BlackRock recently shifted more than $296 million in Bitcoin (BTC) to Coinbase Prime, according to on-chain trackers at Lookonchain.

The large transfers landed just hours before the U.S. Federal Reserve confirmed a 25-basis-point rate cut, adding fresh tension to an already shaky market.

The timing has drawn traders into a debate over whether these moves signal strategic custody changes or preparations to sell amid heightened volatility.

Fresh Transfers Raise Questions as Fed Decision Hits Markets

According to Lookonchain, SpaceX moved another 1,021 BTC, worth around $94 million, to a Coinbase Prime-linked address on December 10, continuing a pattern of weekly transfers near the $100 million mark over the past two months. The firm had shifted 1,083 BTC five days earlier, following a series of similar transactions stretching back to October.

BlackRock made an even larger move, depositing 2,196 BTC valued at about $203 million to Coinbase Prime within the same 24-hour window. Social media reaction split quickly. Some market watchers, like Ted Pillows, worried that it signaled “more selling,” while others, such as 0xNobler, accused the asset manager of applying pressure ahead of the Fed announcement.

At the same time, several bullish accounts highlighted that BlackRock’s ETF bought roughly $191 million in Bitcoin and $55 million in Ethereum (ETH), adding to the confusion about whether the firm is accumulating or trimming exposure.

The SpaceX transfers also came amid intense speculation about the company’s future. As reported by Bloomberg, SpaceX is seen as a potential candidate for a historic initial public offering, with chatter about a Starlink spinoff and a staggering private valuation estimated at up to $1.5 trillion.

Market Backdrop, Price Action, and What Comes Next

The timing of these transfers has amplified market unease. They occurred just as the price of BTC experienced notable volatility, dropping from a brief spike above $94,500 on December 10 to around $90,000 at press time.

Price ranges remain wide: BTC moved between $89,000 and $94,000 in the past 24 hours and between $88,000 and $94,000 across the past week, reflecting the unsettled atmosphere around monetary policy expectations.

Furthermore, over the past month, the asset has fallen by more than 14%, lagging behind ETH and several top altcoins that saw stronger rebounds earlier in the week.

Despite the turbulence, market structure may be steadier than headlines suggest. Coinbase Institutional recently noted that speculative positioning has cooled from summer levels, which they believe could support a more stable trend as December progresses.

For now, the core question remains whether SpaceX and BlackRock’s transfers represent routine storage adjustments or preparations for liquidity events during an uncertain macro window. With BTC down more than 28% from its October all-time high and Fed policy still shaping sentiment, traders are watching the next wallet movements closely.

The post SpaceX, BlackRock Shift $296M in Bitcoin: Sell-Off Signal Ahead? appeared first on CryptoPotato.

Market Opportunity
Bitcoin Logo
Bitcoin Price(BTC)
$69,075.06
$69,075.06$69,075.06
-0.74%
USD
Bitcoin (BTC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26